Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now. On June 23, Aclaris ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

HXN-1001 is a half-life extended next-generation anti-TL1A antibody with great potential for the treatment of patients with inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

A breakthrough in cancer therapy: metal-phenolic nanocarriers deliver antibodies directly to cancer cells, improving ...

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

RM-0256 is an antibody conjugate comprised of a proprietary anti-PD-L1 monoclonal antibody (immune checkpoint inhibitor) and IRDye® 700DX, a light-activatable dye, that has been developed by ...

The Food and Drug Administration (FDA) has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody, for the treatment of celiac disease. Celiac disease is ...

IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.. If you have the appropriate software ...